1. Home
  2. CSW vs NAMS Comparison

CSW vs NAMS Comparison

Compare CSW & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CSW Industrials Inc.

CSW

CSW Industrials Inc.

HOLD

Current Price

$284.87

Market Cap

4.2B

Sector

Industrials

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$34.03

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSW
NAMS
Founded
2014
2019
Country
United States
Netherlands
Employees
2600
100
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
3.5B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CSW
NAMS
Price
$284.87
$34.03
Analyst Decision
Hold
Strong Buy
Analyst Count
5
8
Target Price
$321.40
$46.75
AVG Volume (30 Days)
120.7K
811.1K
Earning Date
05-21-2026
05-07-2026
Dividend Yield
0.35%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$23.19
$17.96
Revenue Next Year
$18.95
$540.65
P/E Ratio
$40.25
N/A
Revenue Growth
N/A
N/A
52 Week Low
$230.45
$15.82
52 Week High
$337.02
$42.00

Technical Indicators

Market Signals
Indicator
CSW
NAMS
Relative Strength Index (RSI) 55.01 55.01
Support Level $284.40 $29.73
Resistance Level $333.30 $37.43
Average True Range (ATR) 11.55 1.77
MACD 4.79 0.38
Stochastic Oscillator 56.87 64.34

Price Performance

Historical Comparison
CSW
NAMS

About CSW CSW Industrials Inc.

CSW Industrials Inc is a diversified industrial growth company with well-established, scalable platforms and domain expertise across three segments, Contractor Solutions, Engineered Building Solutions, and Specialized Reliability Solutions. The company's Contractor Solutions segment involves manufacturing efficient and performance-enhancing products for residential and commercial HVAC/R and plumbing applications, which are designed for professional end-use customers. Majority of the company revenue is generated from Contractor Solutions segment from U.S. markets.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: